SG7 Stock Overview
A biopharmaceutical company, develops and commercializes brain health medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sage Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.96 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$4.47 |
| Beta | 0.92 |
| 11 Month Change | -32.90% |
| 3 Month Change | -31.17% |
| 1 Year Change | -71.66% |
| 33 Year Change | -85.76% |
| 5 Year Change | -96.43% |
| Change since IPO | -75.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| SG7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.4% | -0.2% | 0.8% |
| 1Y | -71.7% | -16.9% | 9.1% |
Return vs Industry: SG7 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: SG7 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| SG7 volatility | |
|---|---|
| SG7 Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SG7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SG7's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 487 | Barry Greene | www.sagerx.com |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
Sage Therapeutics, Inc. Fundamentals Summary
| SG7 fundamental statistics | |
|---|---|
| Market cap | €301.34m |
| Earnings (TTM) | -€321.66m |
| Revenue (TTM) | €101.38m |
3.0x
P/S Ratio-1.0x
P/E RatioIs SG7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SG7 income statement (TTM) | |
|---|---|
| Revenue | US$106.40m |
| Cost of Revenue | US$265.56m |
| Gross Profit | -US$159.16m |
| Other Expenses | US$178.44m |
| Earnings | -US$337.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.52 |
| Gross Margin | -149.58% |
| Net Profit Margin | -317.29% |
| Debt/Equity Ratio | 0% |
How did SG7 perform over the long term?
See historical performance and comparison